Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 744

1.

Prospective assessment of NGS-detectable mutations in CML patients with non-optimal response: the NEXT-in-CML study.

Soverini S, Bavaro L, De Benedittis C, Martelli M, Iurlo A, Orofino N, Sica S, Sora F, Lunghi F, Ciceri F, Galimberti S, Baratè C, Bonifacio M, Scaffidi L, Castagnetti F, Gugliotta G, Albano F, Russo Rossi AV, Stagno F, Di Raimondo F, D'Adda M, Di Bona E, Abruzzese E, Binotto G, Sancetta R, Salvucci M, Capodanno I, Girasoli M, Coluzzi S, Attolico I, Musolino C, Calistri E, Annunziata M, Bocchia M, Stella S, Serra A, Errichiello S, Saglio G, Pane F, Vigneri PG, Mignone F, Laginestra MA, Pileri SA, Percesepe A, Tenti E, Rosti G, Baccarani M, Cavo M, Martinelli G.

Blood. 2019 Dec 26. pii: blood.2019002969. doi: 10.1182/blood.2019002969. [Epub ahead of print]

PMID:
31877211
2.

Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP.

Baccarani M, Abruzzese E, Accurso V, Albano F, Annunziata M, Barulli S, Beltrami G, Bergamaschi M, Binotto G, Bocchia M, Caocci G, Capodanno I, Cavazzini F, Cedrone M, Cerrano M, Crugnola M, D'Adda M, Elena C, Fava C, Fazi P, Fozza C, Galimberti S, Giai V, Gozzini A, Gugliotta G, Iurlo A, La Barba G, Levato L, Lucchesi A, Luciano L, Lunghi F, Lunghi M, Malagola M, Marasca R, Martino B, Melpignano A, Miggiano MC, Montefusco E, Musolino C, Palmieri F, Pregno P, Rapezzi D, Rege-Cambrin G, Rupoli S, Salvucci M, Sancetta R, Sica S, Spadano R, Stagno F, Tiribelli M, Tomassetti S, Trabacchi E, Bonifacio M, Breccia M, Castagnetti F, Pane F, Russo D, Saglio G, Soverini S, Vigneri P, Rosti G.

Blood Adv. 2019 Dec 23;3(24):4280-4290. doi: 10.1182/bloodadvances.2019000865.

3.

Consistency matters: measurement invariance of the EORTC QLQ-C30 questionnaire in patients with hematologic malignancies.

Sommer K, Cottone F, Aaronson NK, Fayers P, Fazi P, Rosti G, Angelucci E, Gaidano G, Venditti A, Voso MT, Baccarani M, Vignetti M, Efficace F.

Qual Life Res. 2019 Nov 28. doi: 10.1007/s11136-019-02369-5. [Epub ahead of print]

PMID:
31782016
4.

Validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Summary Score in Patients With Hematologic Malignancies.

Efficace F, Cottone F, Sommer K, Kieffer J, Aaronson N, Fayers P, Groenvold M, Caocci G, Lo Coco F, Gaidano G, Niscola P, Baccarani M, Rosti G, Venditti A, Angelucci E, Fazi P, Vignetti M, Giesinger J.

Value Health. 2019 Nov;22(11):1303-1310. doi: 10.1016/j.jval.2019.06.004. Epub 2019 Aug 7.

PMID:
31708068
5.

In Ph+BCR-ABL1P210+ acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent.

Baccarani M, Iacobucci I, Chiaretti S, Foà' R, Balasubramanian P, Paietta E, Foroni L, Jeromin S, Izzo B, Spinelli O, Varma N, Menif S, Terragna C, Seth T, Bidet A, Coriu D, Lunghi F, Mayer J, Scappini B, Langabeer S, Maier J, Burt E, Candoni A, Albano F, Luppi M, Zupan I, Lion T, Zadro R, di Raimondo F, Poopak B, Rege-Cambrin G, Annunziata M, Ayala A, Salinas-Viedma V, Ines Prado A, Milner B, Galimberti S, Janssen J, Polli V, Comba L, Borsellino B, Annibali O, Crugnola M, Passamonti F.

Leukemia. 2019 Oct 8. doi: 10.1038/s41375-019-0591-9. [Epub ahead of print] No abstract available.

PMID:
31595038
6.

Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin.

Lauseker M, Bachl K, Turkina A, Faber E, Prejzner W, Olsson-Strömberg U, Baccarani M, Lomaia E, Zackova D, Ossenkoppele G, Griskevicius L, Schubert-Fritschle G, Sacha T, Heibl S, Koskenvesa P, Bogdanovic A, Clark RE, Guilhot J, Hoffmann VS, Hasford J, Hochhaus A, Pfirrmann M.

Am J Hematol. 2019 Nov;94(11):1236-1243. doi: 10.1002/ajh.25628. Epub 2019 Sep 14.

PMID:
31456269
7.

Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type.

Baccarani M, Rosti G, Soverini S.

Leukemia. 2019 Oct;33(10):2358-2364. doi: 10.1038/s41375-019-0562-1. Epub 2019 Aug 27. Review.

PMID:
31455852
8.

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.

Fava C, Rege-Cambrin G, Dogliotti I, Cerrano M, Berchialla P, Dragani M, Rosti G, Castagnetti F, Gugliotta G, Martino B, Gambacorti-Passerini C, Abruzzese E, Elena C, Pregno P, Gozzini A, Capodanno I, Bergamaschi M, Crugnola M, Bocchia M, Galimberti S, Rapezzi D, Iurlo A, Cattaneo D, Latagliata R, Breccia M, Cedrone M, Santoro M, Annunziata M, Levato L, Stagno F, Cavazzini F, Sgherza N, Giai V, Luciano L, Russo S, Musto P, Caocci G, Sorà F, Iuliano F, Lunghi F, Specchia G, Pane F, Ferrero D, Baccarani M, Saglio G.

Haematologica. 2019 Aug;104(8):1589-1596. doi: 10.3324/haematol.2018.205054. Epub 2019 Feb 28.

9.

The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview.

Baccarani M, Castagnetti F, Gugliotta G, Rosti G, Soverini S, Albeer A, Pfirrmann M; International BCR-ABL Study Group.

Leukemia. 2019 May;33(5):1173-1183. doi: 10.1038/s41375-018-0341-4. Epub 2019 Jan 23.

10.

Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.

Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Lustgarten S, Rivera VM, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Shah NP, Kantarjian HM.

Blood. 2018 Jul 26;132(4):393-404. doi: 10.1182/blood-2016-09-739086. Epub 2018 Mar 22.

11.

Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib.

Efficace F, Castagnetti F, Martino B, Breccia M, D'Adda M, Angelucci E, Stagno F, Cottone F, Malato A, Trabacchi E, Capalbo SF, Gobbi M, Visani G, Salvucci M, Capodanno I, Tosi P, Tiribelli M, Scortechini AR, Levato L, Maino E, Binotto G, Gugliotta G, Vignetti M, Baccarani M, Rosti G.

Cancer. 2018 May 15;124(10):2228-2237. doi: 10.1002/cncr.31323. Epub 2018 Mar 2.

12.

Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial.

Candoni A, Papayannidis C, Martinelli G, Simeone E, Gottardi M, Iacobucci I, Gherlinzoni F, Visani G, Baccarani M, Fanin R.

Am J Hematol. 2018 May;93(5):655-663. doi: 10.1002/ajh.25057. Epub 2018 Mar 2.

13.

Physicians' attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients.

Breccia M, Baccarani M, Rosti G, Cottone F, Cannella L, Guilhot F, Vignetti M, Efficace F.

Health Qual Life Outcomes. 2017 Oct 18;15(1):204. doi: 10.1186/s12955-017-0788-4.

14.

Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series.

Iurlo A, Galimberti S, Abruzzese E, Annunziata M, Bonifacio M, Latagliata R, Pregno P, Ferrero D, Sorà F, Orlandi EM, Fava C, Cattaneo D, Bucelli C, Binotto G, Pungolino E, Tiribelli M, Gozzini A, Gugliotta G, Castagnetti F, Stagno F, Rege-Cambrin G, Martino B, Luciano L, Breccia M, Sica S, Bocchia M, Pane F, Saglio G, Rosti G, Specchia G, Cortelezzi A, Baccarani M.

Ann Hematol. 2018 Jan;97(1):95-100. doi: 10.1007/s00277-017-3144-1. Epub 2017 Oct 2.

PMID:
28971265
15.

Chronic myeloid leukemia: room for improvement?

Baccarani M, Pane F, Rosti G, Russo D, Saglio G.

Haematologica. 2017 Jul;102(7):1131-1133. doi: 10.3324/haematol.2017.166280. No abstract available.

16.

Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia.

Gugliotta G, Castagnetti F, Breccia M, Albano F, Iurlo A, Intermesoli T, Abruzzese E, Levato L, D'Adda M, Pregno P, Cavazzini F, Stagno F, Martino B, La Barba G, Sorà F, Tiribelli M, Bigazzi C, Binotto G, Bonifacio M, Caracciolo C, Soverini S, Foà R, Cavo M, Martinelli G, Pane F, Saglio G, Baccarani M, Rosti G; Gruppo Italiano Malattie Ematologiche dell’Adulto - Chronic Myeloid Leukemia Working Party.

Haematologica. 2017 Sep;102(9):1530-1536. doi: 10.3324/haematol.2017.169532. Epub 2017 Jun 1.

17.

New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?

Patriarca F, Giaccone L, Onida F, Castagna L, Sarina B, Montefusco V, Mussetti A, Mordini N, Maino E, Greco R, Peccatori J, Festuccia M, Zaja F, Volpetti S, Risitano A, Bassan R, Corradini P, Ciceri F, Fanin R, Baccarani M, Rambaldi A, Bonifazi F, Bruno B.

Expert Opin Biol Ther. 2017 Jul;17(7):821-836. doi: 10.1080/14712598.2017.1324567. Epub 2017 May 22. Review.

PMID:
28506131
18.

The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.

Castagnetti F, Gugliotta G, Breccia M, Iurlo A, Levato L, Albano F, Vigneri P, Abruzzese E, Rossi G, Rupoli S, Cavazzini F, Martino B, Orlandi E, Pregno P, Annunziata M, Usala E, Tiribelli M, Sica S, Bonifacio M, Fava C, Gherlinzoni F, Bocchia M, Soverini S, Bochicchio MT, Cavo M, Giovanni M, Saglio G, Pane F, Baccarani M, Rosti G; GIMEMA CML Working Party.

Am J Hematol. 2017 Aug;92(8):797-805. doi: 10.1002/ajh.24774. Epub 2017 May 30.

19.

Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy.

Luatti S, Baldazzi C, Marzocchi G, Ameli G, Bochicchio MT, Soverini S, Castagnetti F, Tiribelli M, Gugliotta G, Martinelli G, Baccarani M, Cavo M, Rosti G, Testoni N.

Oncotarget. 2017 May 2;8(18):29906-29913. doi: 10.18632/oncotarget.15369.

20.

Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia.

Hoffmann VS, Hasford J, Deininger M, Cortes J, Baccarani M, Hehlmann R.

J Cancer Res Clin Oncol. 2017 Jul;143(7):1311-1318. doi: 10.1007/s00432-017-2385-7. Epub 2017 Mar 8. Review.

PMID:
28275866
21.

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.

Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O'Brien SG, Druker BJ; IRIS Investigators.

N Engl J Med. 2017 Mar 9;376(10):917-927. doi: 10.1056/NEJMoa1609324.

22.

Treatment-free remission in chronic myeloid leukemia: floating between expectation and evidence.

Baccarani M.

Leukemia. 2017 Apr;31(4):1015-1016. doi: 10.1038/leu.2017.20. Epub 2017 Feb 3. No abstract available.

PMID:
28093565
23.

No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib.

Pfirrmann M, Evtimova D, Saussele S, Castagnetti F, Cervantes F, Janssen J, Hoffmann VS, Gugliotta G, Hehlmann R, Hochhaus A, Hasford J, Baccarani M.

J Cancer Res Clin Oncol. 2017 May;143(5):843-850. doi: 10.1007/s00432-016-2321-2. Epub 2017 Jan 12.

PMID:
28083711
24.

Reply to Constance et al.

Steegmann JL, Baccarani M, Clark RE.

Leukemia. 2017 Mar;31(3):772-773. doi: 10.1038/leu.2016.337. Epub 2016 Dec 6. No abstract available.

PMID:
27922619
25.

Nilotinib against high dose imatinib for salvage therapy of chronic myeloid leukaemia.

Soverini S, Baccarani M, Martinelli G.

Lancet Haematol. 2016 Dec;3(12):e554-e555. doi: 10.1016/S2352-3026(16)30170-3. No abstract available.

PMID:
27890072
26.

Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?

Rosti G, Castagnetti F, Gugliotta G, Baccarani M.

Nat Rev Clin Oncol. 2017 Mar;14(3):141-154. doi: 10.1038/nrclinonc.2016.139. Epub 2016 Oct 18. Review.

PMID:
27752053
27.

Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapies.

Efficace F, Breccia M, Cottone F, Okumura I, Doro M, Riccardi F, Rosti G, Baccarani M.

Support Care Cancer. 2016 Dec;24(12):4887-4894. Epub 2016 Jul 23.

PMID:
27448405
28.

A population-based study of chronic myeloid leukemia patients treated with imatinib in first line.

Castagnetti F, Di Raimondo F, De Vivo A, Spitaleri A, Gugliotta G, Fabbiano F, Capodanno I, Mannina D, Salvucci M, Antolino A, Marasca R, Musso M, Crugnola M, Impera S, Trabacchi E, Musolino C, Cavazzini F, Mineo G, Tosi P, Tomaselli C, Rizzo M, Siragusa S, Fogli M, Ragionieri R, Zironi A, Soverini S, Martinelli G, Cavo M, Vigneri P, Stagno F, Rosti G, Baccarani M.

Am J Hematol. 2017 Jan;92(1):82-87. doi: 10.1002/ajh.24591. Epub 2016 Nov 18.

29.

Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion.

Breccia M, Pregno P, Spallarossa P, Arboscello E, Ciceri F, Giorgi M, Grossi A, Mallardo M, Nodari S, Ottolini S, Sala C, Tortorella G, Rosti G, Pane F, Minotti G, Baccarani M.

Ann Hematol. 2017 Apr;96(4):549-558. doi: 10.1007/s00277-016-2820-x. Epub 2016 Sep 30. Review.

PMID:
27686083
30.

Treatment and outcome of 2904 CML patients from the EUTOS population-based registry.

Hoffmann VS, Baccarani M, Hasford J, Castagnetti F, Di Raimondo F, Casado LF, Turkina A, Zackova D, Ossenkoppele G, Zaritskey A, Höglund M, Simonsson B, Indrak K, Sninska Z, Sacha T, Clark R, Bogdanovic A, Hellmann A, Griskevicius L, Schubert-Fritschle G, Sertic D, Guilhot J, Lejniece S, Zupan I, Burgstaller S, Koskenvesa P, Everaus H, Costeas P, Lindoerfer D, Rosti G, Saussele S, Hochhaus A, Hehlmann R.

Leukemia. 2017 Mar;31(3):593-601. doi: 10.1038/leu.2016.246. Epub 2016 Aug 29.

PMID:
27568522
31.

New strategies in myelofibrosis: the evolving paradigm of disease pathogenesis, prognostication and treatment.

Palandri F, Auteri G, Baccarani M.

Hematol Oncol. 2017 Jun;35(2):145-150. doi: 10.1002/hon.2324. Epub 2016 Aug 10. Review.

PMID:
27510853
32.

Assessment of Minimal Residual Disease in Standard-Risk AML.

Baccarani M.

N Engl J Med. 2016 Aug 11;375(6):e9. doi: 10.1056/NEJMc1603847. No abstract available.

PMID:
27509125
33.

Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients.

Dorer DJ, Knickerbocker RK, Baccarani M, Cortes JE, Hochhaus A, Talpaz M, Haluska FG.

Leuk Res. 2016 Sep;48:84-91. doi: 10.1016/j.leukres.2016.07.007. Epub 2016 Jul 22.

34.

In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.

Soverini S, De Benedittis C, Castagnetti F, Gugliotta G, Mancini M, Bavaro L, Machova Polakova K, Linhartova J, Iurlo A, Russo D, Pane F, Saglio G, Rosti G, Cavo M, Baccarani M, Martinelli G.

BMC Cancer. 2016 Aug 2;16:572. doi: 10.1186/s12885-016-2635-0.

35.

Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients.

Castagnetti F, Breccia M, Gugliotta G, Martino B, D'Adda M, Stagno F, Carella AM, Avanzini P, Tiribelli M, Trabacchi E, Visani G, Gobbi M, Salvucci M, Levato L, Binotto G, Capalbo SF, Bochicchio MT, Soverini S, Cavo M, Martinelli G, Alimena G, Pane F, Saglio G, Rosti G, Baccarani M; GIMEMA CML Working Party.

Haematologica. 2016 Oct;101(10):1200-1207. Epub 2016 Jul 28.

36.

Management of pregnant chronic myeloid leukemia patients.

Abruzzese E, Trawinska MM, de Fabritiis P, Baccarani M.

Expert Rev Hematol. 2016 Aug;9(8):781-91. doi: 10.1080/17474086.2016.1205479. Epub 2016 Jul 7. Review.

PMID:
27352939
37.

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.

Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C, Shah NP, Chuah C, Casanova L, Bradley-Garelik B, Manos G, Hochhaus A.

J Clin Oncol. 2016 Jul 10;34(20):2333-40. doi: 10.1200/JCO.2015.64.8899. Epub 2016 May 23.

38.

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.

Steegmann JL, Baccarani M, Breccia M, Casado LF, García-Gutiérrez V, Hochhaus A, Kim DW, Kim TD, Khoury HJ, Le Coutre P, Mayer J, Milojkovic D, Porkka K, Rea D, Rosti G, Saussele S, Hehlmann R, Clark RE.

Leukemia. 2016 Aug;30(8):1648-71. doi: 10.1038/leu.2016.104. Epub 2016 Apr 28. Review.

39.

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.

Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S, Etienne G, Nicolini FE, le Coutre P, Clark RE, Stenke L, Andorsky D, Oehler V, Lustgarten S, Rivera VM, Clackson T, Haluska FG, Baccarani M, Cortes JE, Guilhot F, Hochhaus A, Hughes T, Kantarjian HM, Shah NP, Talpaz M, Deininger MW; EPIC investigators.

Lancet Oncol. 2016 May;17(5):612-21. doi: 10.1016/S1470-2045(16)00080-2. Epub 2016 Apr 12.

PMID:
27083332
40.

Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients.

Soverini S, De Benedittis C, Polakova KM, Linhartova J, Castagnetti F, Gugliotta G, Papayannidis C, Mancini M, Klamova H, Salvucci M, Crugnola M, Iurlo A, Albano F, Russo D, Rosti G, Cavo M, Baccarani M, Martinelli G.

Oncotarget. 2016 Apr 19;7(16):21982-90. doi: 10.18632/oncotarget.8010.

41.

Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia.

Gugliotta G, Castagnetti F, Breccia M, Gozzini A, Usala E, Carella AM, Rege-Cambrin G, Martino B, Abruzzese E, Albano F, Stagno F, Luciano L, D'Adda M, Bocchia M, Cavazzini F, Tiribelli M, Lunghi M, Pia Falcone A, Musolino C, Levato L, Venturi C, Soverini S, Cavo M, Alimena G, Pane F, Martinelli G, Saglio G, Rosti G, Baccarani M; GIMEMA CML Working Party.

Am J Hematol. 2016 Jun;91(6):617-22. doi: 10.1002/ajh.24362. Epub 2016 Apr 24.

42.

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.

Padula WV, Larson RA, Dusetzina SB, Apperley JF, Hehlmann R, Baccarani M, Eigendorff E, Guilhot J, Guilhot F, Hehlmann R, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Saussele S, Schiffer CA, Silver RT, Simonsson B, Conti RM.

J Natl Cancer Inst. 2016 Mar 4;108(7). doi: 10.1093/jnci/djw003. Print 2016 Jul.

43.

Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives.

Malagola M, Papayannidis C, Baccarani M.

Ann Hematol. 2016 Apr;95(5):681-93. doi: 10.1007/s00277-016-2617-y. Epub 2016 Feb 19. Review.

PMID:
26891878
44.

Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients.

Soverini S, De Benedittis C, Papayannidis C, Polakova KM, Venturi C, Russo D, Bresciani P, Iurlo A, Mancini M, Vitale A, Chiaretti S, Foà R, Abruzzese E, Sorà F, Kohlmann A, Haferlach T, Baccarani M, Cavo M, Martinelli G.

Leukemia. 2016 Jul;30(7):1615-9. doi: 10.1038/leu.2016.17. Epub 2016 Feb 12. No abstract available.

PMID:
26867670
45.

Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study.

Martinelli G, Oehler VG, Papayannidis C, Courtney R, Shaik MN, Zhang X, O'Connell A, McLachlan KR, Zheng X, Radich J, Baccarani M, Kantarjian HM, Levin WJ, Cortes JE, Jamieson C.

Lancet Haematol. 2015 Aug;2(8):e339-46. doi: 10.1016/S2352-3026(15)00096-4. Epub 2015 Jul 26.

PMID:
26688487
46.

Prediction of response and survival in patients with chronic-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate: logistic regression and landmark analyses.

Wetzler M, Kantarjian HM, Nicolini FE, Lipton JH, Akard L, Baccarani M, Khoury HJ, Li E, Munteanu M, Cortes J.

Blood Cancer J. 2015 Dec 11;5:e376. doi: 10.1038/bcj.2015.104. No abstract available.

47.

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.

Deininger MW, Hodgson JG, Shah NP, Cortes JE, Kim DW, Nicolini FE, Talpaz M, Baccarani M, Müller MC, Li J, Parker WT, Lustgarten S, Clackson T, Haluska FG, Guilhot F, Kantarjian HM, Soverini S, Hochhaus A, Hughes TP, Rivera VM, Branford S.

Blood. 2016 Feb 11;127(6):703-12. doi: 10.1182/blood-2015-08-660977. Epub 2015 Nov 24.

48.

The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia.

Efficace F, Rosti G, Breccia M, Cottone F, Giesinger JM, Stagno F, Iurlo A, Russo Rossi A, Luciano L, Martino B, Galimberti S, Turri D, Bergamaschi M, Tiribelli M, Fava C, Angelucci E, Mandelli F, Baccarani M.

Ann Hematol. 2016 Jan;95(2):211-9. doi: 10.1007/s00277-015-2541-6. Epub 2015 Nov 7.

PMID:
26546359
49.

Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study.

Hochhaus A, Rosti G, Cross NC, Steegmann JL, le Coutre P, Ossenkoppele G, Petrov L, Masszi T, Hellmann A, Griskevicius L, Wiktor-Jedrzejczak W, Rea D, Coriu D, Brümmendorf TH, Porkka K, Saglio G, Gastl G, Müller MC, Schuld P, Di Matteo P, Pellegrino A, Dezzani L, Mahon FX, Baccarani M, Giles FJ.

Leukemia. 2016 Jan;30(1):57-64. doi: 10.1038/leu.2015.270. Epub 2015 Oct 6.

50.

Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate.

Akard L, Kantarjian HM, Nicolini FE, Wetzler M, Lipton JH, Baccarani M, Jean Khoury H, Kurtin S, Li E, Munteanu M, Cortes J.

Leuk Lymphoma. 2016;57(3):654-65. doi: 10.3109/10428194.2015.1071486. Epub 2015 Oct 5.

Supplemental Content

Loading ...
Support Center